inclusion criteria: 1. adults aged 18 years and above. 2. confirmed sars-cov-2 infection by pcr/rt-pcr. patients with positive point of care tests can be randomised but have to be confirmed for sars-cov-2 by rt-pcr. 3. presence of symptoms consistent with covid-19 (e.g. shortness of breath, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia). 4. who 10-point clinical progression scale score of 4 to 5 5. patient requires hospitalisation due to severity of covid-19 or comorbidities if score 3 on the who 10-point clinical progression scale. 6. frailty score of ≤6. 7. patient able to provide informed consent. 8. females of child-bearing potential must be non-lactating, must have a negative pregnancy test at screening, and must agree to continue using contraception throughout the study and for 4 weeks after study completion.

inclusion criteria: 1. adults aged 18 years and above. 2. confirmed sars-cov-2 infection by pcr/rt-pcr. patients with positive point of care tests can be randomised but have to be confirmed for sars-cov-2 by rt-pcr. 3. presence of symptoms consistent with covid-19 (e.g. shortness of breath, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia). 4. who 10-point clinical progression scale score of 4 to 5 5. patient requires hospitalisation due to severity of covid-19 or comorbidities if score 3 on the who 10-point clinical progression scale. 6. frailty score of ≤6. 7. patient able to provide informed consent. 8. females of child-bearing potential must be non-lactating, must have a negative pregnancy test at screening, and must agree to continue using contraception throughout the study and for 4 weeks after study completion.

inclusion criteria: adults aged 18 years and above. confirmed sars-cov-2 infection by pcr/rt-pcr. patients with positive point of care tests can be randomised but have to be confirmed for sars-cov-2 by rt-pcr. presence of symptoms consistent with covid-19 (e.g. shortness of breath, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia). who 10-point clinical progression scale score of 4 to 5 patient requires hospitalisation due to severity of covid-19 or comorbidities if score 3 on the who 10-point clinical progression scale. frailty score of ≤6. patient able to provide informed consent. females of child-bearing potential must be non-lactating, must have a negative pregnancy test at screening, and must agree to continue using contraception throughout the study and for 4 weeks after study completion.

inclusion criteria: adults aged 18 years and above. confirmed sars-cov-2 infection by pcr/rt-pcr. patients with positive point of care tests can be randomised but have to be confirmed for sars-cov-2 by rt-pcr. presence of symptoms consistent with covid-19 (e.g. shortness of breath, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia). who 10-point clinical progression scale score of 4 to 5 patient requires hospitalisation due to severity of covid-19 or comorbidities if score 3 on the who 10-point clinical progression scale. frailty score of ≤6. patient able to provide informed consent. females of child-bearing potential must be non-lactating, must have a negative pregnancy test at screening, and must agree to continue using contraception throughout the study and for 4 weeks after study completion.

inclusion criteria: 1. adults aged 18 years and above. 2. confirmed sars-cov-2 infection by pcr/rt-pcr. patients with positive point of care tests can be randomised but have to be confirmed for sars-cov-2 by rt-pcr. 3. presence of symptoms consistent with covid-19 (e.g. shortness of breath, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia). 4. who 10-point clinical progression scale score of 4 to 5 5. patient requires hospitalisation due to severity of covid-19 or comorbidities if score 3 on the who 10-point clinical progression scale. 6. frailty score of ≤6. 7. patient able to provide informed consent. 8. females of child-bearing potential must be non-lactating, must have a negative pregnancy test at screening, and must agree to continue using contraception throughout the study and for 4 weeks after study completion.

inclusion criteria: 1. adults aged 18 years and above. 2. confirmed sars-cov-2 infection by pcr/rt-pcr. patients with positive point of care tests can be randomised but have to be confirmed for sars-cov-2 by rt-pcr. 3. presence of symptoms consistent with covid-19 (e.g. shortness of breath, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia). 4. who 10-point clinical progression scale score of 4 to 5 5. patient requires hospitalisation due to severity of covid-19 or comorbidities if score 3 on the who 10-point clinical progression scale. 6. frailty score of ≤6. 7. patient able to provide informed consent. 8. females of child-bearing potential must be non-lactating, must have a negative pregnancy test at screening, and must agree to continue using contraception throughout the study and for 4 weeks after study completion.